Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK rearrangements represent the molecular driver of a subset of solid tumors, including 3% of non-small-cell lung cancers (NSCLCs). Preliminary data ind...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2017-06, Vol.34 (6), p.105-105, Article 105
Hauptverfasser:	Ricciuti, Biagio, Brambilla, Marta, Metro, Giulio, Baglivo, Sara, Matocci, Roberta, Pirro, Matteo, Chiari, Rita
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Gene Rearrangement - genetics Hematology Humans Internal Medicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medicine Medicine & Public Health Membrane Glycoproteins - genetics Oncogene Proteins, Fusion - genetics Oncology Pathology Pharmaceutical industry Precision Medicine - methods Protein Kinase Inhibitors Pyrazoles Pyrimidines Receptor, trkB - genetics Review Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!